# A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

> **NCT07733947** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514 Injection
- **DRUG:** 0.9 % sodium chloride

## Key facts

- **NCT ID:** NCT07733947
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-08
- **Final completion:** 2028-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733947, "A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07733947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*